Highlight selection of radiochemistry and radiopharmacy developments by editorial board
Tóm tắt
The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development. This selection of highlights provides commentary on 21
different topics selected by each coauthoring Editorial Board member addressing
a variety of aspects ranging from novel radiochemistry to first-in-human
application of novel radiopharmaceuticals. Trends in radiochemistry and radiopharmacy are
highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and
Chemistry, demonstrating the progress in the research field, and include new
PET-labelling methods for 11C and 18F, the importance of
choosing the proper chelator for a given radioactive metal ion, implications of
total body PET on use of radiopharmaceuticals, legislation issues and
radionuclide therapy including the emerging role of 161Tb.
Tài liệu tham khảo
Barnes C, Nair M, Aboagye EO, Archibald SJ, Allott L. A practical guide to automating fluorine-18 PET radiochemistry using commercially available cassette-based platforms. React Chem Eng. 2022;7:2265–79.
Bartos LM, Kunte ST, Beumers P, Xiang X, Wind K, Ziegler S, Bartenstein P, Choi H, Lee DS, Haass C, Baumgarten LV, Tahirovic S, Albert NL, Lindner S, Brendel M. Single-cell radiotracer allocation via immunomagnetic sorting to disentangle PET signals at cellular resolution. J Nucl Med. 2022;63:1459–62.
Borgna F, Haller S, Rodriguez JMM, Ginj M, Grundler PV, Zeevaart JR, Koster U, Schible R, van der Meulen NP, Muller C. Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroeondocrine neoplasms. Eur J Nucl Med Mol Imaging. 2022;49:1113–26.
Bsharat O, Doyle MGJ, Munch M, Mair BA, Cooze CJC, Derdau V, Bauer A, Kong D, Rotstein BH, Lundgren RJ. Radiosynthesis of α-amino acids by exchanging aldehyde-catalyzed carboxylate with 11CO2. Aldehyde-catalysed carboxylate exchange in α-amino acids with isotopically labelled CO2. Nat Chem. 2022;14:1367–74.
CCS Task Force issues new Guideline. Contamination Control Strategy (CCS) A New Guideline from ECA. https://www.eca-foundation.org/news/ccs-task-force-issues-new-guideline.html. Accessed 29 Jan 2023.
Chen Z, Chen J, Chen L, Yoo C-H, Rong J, Fu H, Shao T, Coffman K, Steyn SJ, Davenport AT, Daunais JB, Haider A, Collier L, Josephson L, Wey H-Y, Zhang L, Liang SH. Imaging leucine-rich repeat kinase 2 in vivo with 18F-labeled positron emission tomography ligand. J Med Chem. 2022. https://doi.org/10.1021/acs.jmedchem.2c00551. Online ahead of print.
De Man K, van Laeken N, Schelfhout V, Fendler WP, Lambert B, Kersemans K, Piron S, Lumen N, Decaestecker K, Fonteyne V, Delrue L, de Vos F, Ost P. Eur Urol. 2022;82:501–9.
de Vries EFJ, Elsinga PH, Tsoumpas C. Will extended field-of-view PET/CT depopulate the graveyard of failed PET radiopharmaceuticals? Cancer Imaging. 2022;22:70.
EudraLex -. Volume 4 - Good Manufacturing Practice (GMP) guidelines, Annex 1: Manufacture of Sterile Medicinal Products. https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en. Accessed 29 Jan 2023.
Giesel FL, Adeberg S, Syed M, Lindner T, Jimenez-Franco LD, Mavriopoulou E, Staundinger F, Tonndorf-Martini E, Regnery S, Rieken S, El Shafie R, Rohrich M, Flechsig P, Kluge A, Altmann A, Debus J, Haberkorn U, Kratochwil C. FAPI-74 PET/CT using either 18F-AlF or cold-kit 68Ga labelling: bioditribution, radiation dosimetry, and tumor delineation in lung cancer patients. J Nucl Med. 2021;62:201–7.
Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, Erchegyi J, Rivier J, Maecke HR, Reubi JC. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A. 2006;103:16436–41.
IAEA radioisotopes and radiopharmaceuticals. series no. 7. Copper-64 radiopharmaceuticals: production, quality control and clinical applications. International Atomic Energy Agency, Vienna, 2022.
Kadassery A, Paden King S, Fayn KE, Baidoo, Samantha N, MacMillan, Freddy E, Escorcia, Wilson JJ. H2BZmacropa-NCS: a bifunctional chelator for actinium-225 targeted alpha therapy. Bioconjug Chem. 2022;33:1222.
Kinne RW, Emmrich F, Freesmeyer M. Clinical impact of radiolabeled anti-CD4 antibodies in the diagnosis of rheumatoid arthritis. M freesmeyer. Q J Nucl Med Mol Imaging. 2010;54:629–38.
Kiritsis C, Shegani A, Makrypidi K, Roupa I, Lazopoulos A, Panagiotopoulou A, Triantopoulou S, Paravatou-Petsotas M, Pietzsch HJ, Pelecanou M, Papadopoulos M, Pirmettis I. Synthesis and preclinical evaluation of rhenium and technetium-99m “4 + 1” mixed-ligand complexes bearing quinazoline derivatives as potential EGFR imaging agents. Bioorg Med Chem. 2022;73:117012.
Korde A, Mikolajczak R, Kolenc P, Bouziotis P, Westin H, Lauritzen M, Koole M, Herth MM, Bardies M, Martins AF, Paulo A, Lyashchenko SK, Todde S, Nag S, Lamprou E, Abrunhosa A, Giammarile F, Decristoforo C. Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals. EJNMMI Radiopharm Chem. 2022;7:18.
Laferriere-Holloway TS, Rios A, van Dam RM. Detrimental impact of aqueous mobile phases on 18F-labelled radiopharmaceutical analysis via radio-TLC. Anal Methods. 2023;15:377–87.
Laszlo GS, Orozco JJ, Kehret AR, Lunn MC, Huo J, Hamlin DK, Wilbur DS, Dexter SL, Comstock ML, O’Steen S, Sandmaier BM, Green DJ, Walter RB. Development of [211At]astatine-Based Anti-CD123 Radioimmunotherapy for Acute Leukemias and other CD123 + malignancies. Leukemia. 2022;36:1485–91.
McNeil SW, Van de Voorde M, Zhang C, Ooms M, Bénard F, Radchenko V, Yang H. A simple and automated method for 161 Tb purification and ICP-MS analysis of 161 Tb. EJNMMI Radiopharm Chem. 2022;7:31.
Minnix M, Kujawski M, Poku E, Yazaki PJ, Wong JY, Shively JE. Improved tumor responses with sequential targeted α-particles followed by interleukin 2 immunocytokine therapies in treatment of CEA-positive breast and colon tumors in CEA transgenic mice. J Nucl Med. 2022;63:1859–64.
Mota F, Ruiz-Bedoya CA, Tucker EW, Holt DP, De Jesus P, Lodge MA, Erice C, Chen X, Bahr M, Flavahan K, Kim J, Brosnan MK, Ordonez AA, Peloquin CA, Dannals RF, Jain SK. Dynamic 18F-Pretomanid PET imaging in animal models of TB meningitis and human studies. Nat Commun. 2022;13:7974.
Paillas S, Ladjohounlou R, Lozza C, Pichard A, Boudousq V, Jarlier M, Sevestre S, Le Blay M, Deshayes E, Sosabowski J, Chardes T, Navarro-Teulon I, Mairs RJ, Pouget JP. Localized irradiation of cell membrane by Auger electrons is cytotoxic through oxidative stress-mediated nontargeted effects. Antioxid Redox Signal. 2016;25:467–84.
Parental Drug Association. https://www.pda.org/topic-areas/pupsit. Accessed 29 Jan 2023
Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, van Cutsem E, Verslype C, van Laure K, Bormans G, Deroose CM. [18F]AlF-NOTA-octreotide PET-imaging biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2020;47:3033–46.
Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Boeckxstaens L, Dekervel J, Vandamme T, Lybaert W, van den Broeck B, Laenen A, Clement PM, Geboes K, van Cutsem E, Stroobants S, Verslype C, Bormans G, Deroose CM. 18F-AlF-NOTA-octreotide outperforms 68Ga-DOTA-TATE/-NOC PET in neuroendocrine tumor pateints: results from a prospective, multocenter study. J Nucl Med. 2022. https://doi.org/10.2967/jnumed.122.264563.
Raavé R, Sandker G, Adumeau P, Jacobsen CB, Mangin F, Meyer M, Moreau M, Bernhard C, Da Costa L, Dubois A, Goncalves V, Gustafsson M, Rijpkema M, Boerman O, Chambron JC, Heskamp S, Denat F. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89Zr-immunoPET. Eur J Nucl Med Mol Imaging. 2019;46:1966–77.
Sap JBI, Meyer CF, Ford J, Straathof NJW, Dürr AB, Lelos MJ, Paisey SJ, Mollner TA, Hell SM, Trabanco AA, Genicot C, Am Ende CW, Paton RS, Tredwell M, Gouverneur V. [18F]difluorocarbene for positron emission tomography. Nature. 2022;606:102–8.
Shegani A, Kealey S, Luzi F, Basagni F, Machado JDM, Ekici SD, Ferocino A, Gee AD, Bongarzone S. Radiosynthesis, preclinical, and clinical positron emission tomography studies of carbon-11 labeled endogenous and natural exogenous compounds. Chem Rev. 2023;123:105–229.
Skovsbo Clausen A, Christensen C, Christensen E, Cold S, Kellemann Kristensen L, Hansen AE, Kjaer A. Development of a 64Cu-labeled CD4+ T cell targeting PET tracer: evaluation of CD4 specificity and its potential use in collagen-induced arthritis. EJNMMI Res. 2022;12:62.
Takahashi M, Takamoto S. The preparation of trivalent metal chelates with some N3O3type ligands. Bull Chem Soc Jpn. 1977;50:3413.
Verel I, Visser GWM, Boellaard R, Stigter-Walsum M, Snow GB, Van Dongen GA. 89Zr Immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271–81.
Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, Kiefer GE, Van Dongen GA. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5:739–43.
Vugts DJ, Klaver C, Sewing C, Poot AJ, Adamzek K, Huegli S, et al. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET. Eur J Nucl Med Mol Imaging. 2017;44:286–95.
Wei W, Younis MH, Lan X, Liu J, Cai W. Single-domain antibody theranostics on the Horizon. J Nucl Med. 2022;63:1475–9.
Wuensche TE, Stergiou N, Mes I, Verlaan M, Schreurs M, Kooijman EJM, Janssen B, Windhorst AD, Jensen A, Asuni AA, Bang-Andersen B, Beaino W, Dongen GAMS, Vugts DJ. Advancing 89Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody—the choice of chelator is essential. Theranostics. 2022;12:7067–79.